The Liverpool Uveal Melanoma Prognosticator Online (LUMPO) for prognosing metastasis free survival in the absence of cytogenetic data after ruthenium brachytherapy for uveal melanoma

Purpose Liverpool Uveal Melanoma Prognosticator Online (LUMPO) is a tool developed by Eleuteri et al. to establish the prognosis for uveal melanoma patients according to the initial tumour characteristics and cytogenetic data. It has been validated with two separate cohorts of patients in United Kingdom and more recently in US. The aim of this study was to test the prognosticator in a homogenous group of patients treated with ruthenium brachytherapy where genetic analysis was not performed. Material and methods The records of the patients treated with ruthenium brachytherapy for uveal melanoma at the Department of Ophthalmology, Poznan University of Medical Sciences between 1994 and 2012 were retrospectively reviewed. The probability of 3‐, 5‐ and 10‐year metastasis free survival were obtained for each patient using the LUMPO accessed online and then compared with the existing follow‐up data. Results We identified 102 patients, 60 women, 42 men in a mean age of 59 years. Mean largest basal diameter of the treated tumours was 9.29 (range: 4.04–18.9) mm, mean tumour thickness: 4.8 (range: 2.6–7.01) mm. Follow‐up ranged from 3 to 22 years, mean: 7.55 years. 33 patients died, 18 (17.65%) out of metastatic disease. The metastatic death was not related to patients’ age (p = 0.6866), LBD (p = 0.3049) or tumour thickness (p = 0.7063) alone. The probability of metastasis free survival according to LUMPO was significantly lower for the metastatic group comparing to the surviving group at 3 years (p = 0.0017) and 5 years post treatment (p = 0.0001). Conclusions LUMPO is a useful tool for prognostication for uveal melanoma patients. However, the use of cytogenetic data makes this prognosis more precise.